A couple good articles on the trials and tribulation of Big pharma R&D have appeared in the past weeks, the first in Nature Reviews Drug Discovery covering the views of ex-Pfizer R&D chief John LaMattina, and the second appearing in Forbes article by Matt Herper discussing the need for radical change with ex-Lilly Bernard Munos.
I'll let you read the posts commenting on these for yourself from In Vivo and In the Pipeline. Both agree that with most everyone else that the indsutry can't continue to conduct business as it has -- but various models are being tried by various Big Pharma companies and it is not at all clear what the best approaches may be to increasing success. It is clear that most are tryign to diversify their efforts through more outsourcing and partnerships with smaller companies, academia or even each other.
This will continue to be an evolving area and we should all pay attention to see which models seem to start delivering better results.
Posted by Bruce Lehr Aug 5th 2011.